709 results match your criteria Dystonia Tardive

Management of Tardive Syndrome: Medications and Surgical Treatments.

Stewart A Factor

Neurotherapeutics 2020 10;17(4):1694-1712

Jean and Paul Amos Parkinson's Disease and Movement Disorder Program, Emory University School of Medicine, 12 Executive Park Drive Northeast, Atlanta, Georgia, 30329, USA.

Tardive syndrome (TS) is an iatrogenic, often persistent movement disorder caused by drugs that block dopamine receptors. It has a broad phenotype including movement (orobuccolingual stereotypy, dystonia, tics, and others) and nonmotor features (akathisia and pain). TS has garnered increased attention of late because of the Food and Drug Administration approval of the first therapeutic agents developed specifically for this purpose. Read More

View Article and Full-Text PDF
October 2020

Dyskinesia is most centrally situated in an estimated network of extrapyramidal syndrome in Asian patients with schizophrenia: findings from research on Asian psychotropic prescription patterns for antipsychotics.

Nord J Psychiatry 2021 Jan 25;75(1):9-17. Epub 2020 Jun 25.

Department of Psychiatry and Psychobiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan.

Background: Network analysis provides a new viewpoint that explicates intertwined and interrelated symptoms into dynamic causal architectures of symptom clusters. This is a process called 'symptomics' and is concurrently applied to various areas of symptomatology.

Aims: Using the data from Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), we aimed to estimate a network model of extrapyramidal syndrome in patients with schizophrenia. Read More

View Article and Full-Text PDF
January 2021

Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.

BMC Psychiatry 2020 06 16;20(1):308. Epub 2020 Jun 16.

Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France.

Background: Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants and antidepressants' classes. The objective of this study was to assess the putative association of each antidepressant and antidepressants' classes with movement disorders. Read More

View Article and Full-Text PDF

Tardive syndromes.

Pract Neurol 2020 Oct 2;20(5):368-376. Epub 2020 Jun 2.

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.

Dopamine receptor-blocking antipsychotics, first introduced into clinical practice in 1952, were hailed as a panacea in the treatment of a number of psychiatric disorders. However, within 5 years, this notion was to be shattered by the recognition of both acute and chronic drug-induced movement disorders which can accompany their administration. Tardive syndromes, denoting the delayed onset of movement disorders following administration of dopamine receptor-blocking (and also other) drugs, have diverse manifestations ranging from the classic oro-bucco-lingual dyskinesia, through dystonic craniocervical and trunk posturing, to abnormal breathing patterns. Read More

View Article and Full-Text PDF
October 2020

Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.

Parkinsonism Relat Disord 2020 05 14;74:36-37. Epub 2020 Apr 14.

University of Ankara School of Medicine, Department of Neurology, Ankara, Turkey; Department of Interdisciplinary Neuroscience, Ankara University, Institute of Health Sciences, Ankara, Turkey.

View Article and Full-Text PDF

Treatment of Tardive Dyskinesia.

Neurol Clin 2020 05 28;38(2):379-396. Epub 2020 Feb 28.

Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center and Movement Disorders Clinic, 7200 Cambridge, 9th Floor, Suite 9A, Houston, TX 77030-4202, USA. Electronic address:

Tardive dyskinesia (TD) is an iatrogenic condition that encompasses a wide phenomenological spectrum of movement disorders caused by exposure to dopamine receptor blocking agents (DRBAs). TD may cause troublesome or disabling symptoms that impair quality of life. Due to frequent, often inappropriate, use of DRBAs, TD prevalence rates among patients exposed to DRBAs continue to be high. Read More

View Article and Full-Text PDF

Clinical Rating Scales and Quantitative Assessments of Movement Disorders.

Arjun Tarakad

Neurol Clin 2020 05 6;38(2):231-254. Epub 2020 Feb 6.

Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 7200 Cambridge Street Suite 9A, Houston, TX 77030, USA. Electronic address:

This article reviews scales that have been developed for, validated in, and/or frequently used across multiple movement disorders with a focus on assessment of motor and nonmotor symptoms of Parkinson disease. Rating scales used in other disease states include those for essential tremor, dystonia (generalized dystonia, cervical dystonia, and blepharospasm), Tourette syndrome, Huntington disease, tardive dyskinesia, Wilson disease, ataxia, and functional movement disorders. Key features of each scale as well as cited criticisms and limitations of each scale are also discussed. Read More

View Article and Full-Text PDF

Tardive dystonia improved with discontinuation of trazodone in an elderly schizophrenia patient: a case report.

Ann Gen Psychiatry 2020 1;19:23. Epub 2020 Apr 1.

Minamigaoka Hospital, 3-13-1 Imamachi, Kokurakita-ku, Kitakyushu, Fukuoka 8030862 Japan.

Background: Tardive dystonia associated with antidepressant use is rare and often under-recognized. We had an experience with trazodone, which is used for delirium and insomnia prescribed in general hospital, inducing tardive dystonia.

Case Presentation: A 61-year-old Japanese woman had been treated for schizophrenia. Read More

View Article and Full-Text PDF

Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol.

World J Biol Psychiatry 2020 10 5;21(8):612-626. Epub 2020 May 5.

Department of Biochemistry, Nigerian Institute of Medical Research Yaba Lagos, Lagos, Nigeria.

Tardive dyskinesia (TD) unlike acute dystonia may be irreversible. This study investigated the effects of oral cannabidiol (CBD) on haloperidol-induced vacuous chewing movement (VCM) model of TD. There were six experimental groups with different combinations of oral cannabidiol with 5 mg/kg of haloperidol given orally. Read More

View Article and Full-Text PDF
October 2020

The dentato-rubro-thalamic tract as the potential common deep brain stimulation target for tremor of various origin: an observational case series.

Acta Neurochir (Wien) 2020 05 29;162(5):1053-1066. Epub 2020 Jan 29.

Department of Stereotactic and Functional Neurosurgery, Freiburg University Medical Center, Freiburg (i.Br.), Germany.

Introduction: Deep brain stimulation alleviates tremor of various origins. The dentato-rubro-thalamic tract (DRT) has been suspected as a common tremor-reducing structure. Statistical evidence has not been obtained. Read More

View Article and Full-Text PDF

A preliminary exome sequence in three patients with tardive dystonia.

Psychiatr Genet 2020 04;30(2):57-59

Department of Psychiatry, Chiba University Graduate School of Medicine.

Tardive dystonia is one of the most serious adverse events that can be caused by antipsychotic treatment, but few studies have examined the etiology of tardive dystonia, and no genetic study using a next-generation sequencing technique has been performed to date. We conducted exome sequencing in three subjects with severe tardive dystonia. We analyzed the results focusing on candidate genes of primary dystonia, for example, TOR1A, GCH1, TH, THAP1, and SGCE. Read More

View Article and Full-Text PDF

Models of hyperkinetic disorders in primates.

Erwan Bezard

J Neurosci Methods 2020 02 16;332:108551. Epub 2019 Dec 16.

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. Electronic address:

Hyperkinetic movement disorders include tremors, dystonia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with abnormal involuntary movements. Although several disorders could be included in such a broad spectrum, a limited number of conditions are modeled in non-human primates. These disabling conditions include notably L-dopa-induced dyskinesia in Parkinson's disease, tardive dyskinesia, essential tremor and Huntington's disease. Read More

View Article and Full-Text PDF
February 2020

Quality of life outcomes after deep brain stimulation in dystonia: A systematic review.

Parkinsonism Relat Disord 2020 01 18;70:82-93. Epub 2019 Nov 18.

Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.

Dystonia is an incurable movement disorder which can cause not only physical but also mental problems, leading to impaired health-related quality of life (HRQoL). For patients with dystonia refractory to medical treatment, deep brain stimulation (DBS) is a well-established surgical treatment. The objective of this systematic review is to provide a better understanding of HRQoL outcomes after DBS for dystonia. Read More

View Article and Full-Text PDF
January 2020

The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia.

Handb Clin Neurol 2019 ;165:415-428

Department of Psychiatry and Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands.

Although highly prevalent, motor syndromes in psychiatry and motor side effects of psychopharmacologic agents remain understudied. Catatonia is a syndrome with specific motor abnormalities that can be seen in the context of a variety of psychiatric and somatic conditions. The neuroleptic malignant syndrome is a lethal variant, induced by antipsychotic drugs. Read More

View Article and Full-Text PDF

Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes: A Naturalistic Observational Study in Patients With Psychotic Disorders.

J Clin Psychopharmacol 2019 Nov/Dec;39(6):591-596

From the Department of Psychiatry, Sungkyunkwan University School of Medicine, Samsung Medical Center.

Purpose: Given that switching to clozapine is an important treatment option for tardive movement syndrome (TMS), its effect and clinical correlates have not been fully explored yet. This study investigated the improvement of TMS after switching to clozapine and factors associated with the response in a naturalistic outpatient setting.

Methods: Subjects were 35 patients with schizophrenia or bipolar disorder receiving only clozapine as an antipsychotic drug for more than 12 months. Read More

View Article and Full-Text PDF

Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRI.

J Neurosurg 2019 Oct 11:1-13. Epub 2019 Oct 11.

Departments of1Neurology and.

Objective: Lead placement for deep brain stimulation (DBS) using intraoperative MRI (iMRI) relies solely on real-time intraoperative neuroimaging to guide electrode placement, without microelectrode recording (MER) or electrical stimulation. There is limited information, however, on outcomes after iMRI-guided DBS for dystonia. The authors evaluated clinical outcomes and targeting accuracy in patients with dystonia who underwent lead placement using an iMRI targeting platform. Read More

View Article and Full-Text PDF
October 2019

Lurasidone-Induced Tardive Syndrome.

Mov Disord Clin Pract 2019 Sep 24;6(7):601-604. Epub 2019 Jul 24.

Department of Neurology Emory University School of Medicine Atlanta Georgia USA.

Introduction: Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor-blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS.

Methods: Case series. Read More

View Article and Full-Text PDF
September 2019

Recognizing Movement Disorder Emergencies - A Practical Review For Non-Neurologist.

J Ayub Med Coll Abbottabad 2019 Jul-Sep;31(3):448-453

Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, United States.

Neurology still remains one of the most underserved specialties of medicine in Pakistan with roughly one neurologist per million people. Movement disorders (MD) are neurological problems that interfere with patient's motor abilities and diagnosis is typically clinical. In this review, we describe a practical approach to common MD emergencies that may be encountered by a non-neurologist physician, emphasizing on formulating a working diagnosis and their immediate management. Read More

View Article and Full-Text PDF
December 2019

Refractory Open Jaw Oromandibular Tardive Dystonia with a Sensory Trick, Treated with Botulinum Toxin: A Case Report.

Neurol India 2019 Jul-Aug;67(4):1110-1111

Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Jaw-opening oromandibular dystonia (O-OMD) is a clinical subtype of OMD, commonly resistant to treatment. Here, we report a distinct case of tardive O-OMD with a characteristic sensory trick, successfully treated with high-dose botulinum toxin (BTX) injection. A 34-year-old male patient presented with involuntary jaw opening, tongue protrusion, dysarthria, and mild cervical dystonia. Read More

View Article and Full-Text PDF

Analyzing Nanotheraputics-Based Approaches for the Management of Psychotic Disorders.

J Pharm Sci 2019 12 6;108(12):3757-3768. Epub 2019 Sep 6.

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address:

Psychoses are brain disorders clinically manifested by cognitive conditions such as hallucinations, delirium, dementia, schizophrenia, and delusions. Antipsychotic drugs are associated with significant side effects such as dystonia, tardive dyskinesia, involuntary muscle movement, and metabolic disorders. Moreover, those antipsychotics currently available have poor bioavailability, drug-related adverse effects, poor therapeutic efficacy, and poor brain delivery resulting from the blood-brain barrier. Read More

View Article and Full-Text PDF
December 2019

A Possible Case of Escitalopram-Induced Tardive Dystonia.

Psychosomatics 2020 Mar - Apr;61(2):188-192. Epub 2019 Jul 3.

Department of Psychiatry, Dartmouth College Geisel School of Medicine, Hanover, NH; Department of Psychiatry, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

View Article and Full-Text PDF
February 2021

Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration.

Pediatr Neurol 2020 02 13;103:76-78. Epub 2019 Jun 13.

Department of Neurology, Hazrat Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran. Electronic address:

Background: Tongue protrusion dystonia is an uncommon focal dystonia involving the lingual muscles. Causes of tongue protrusion dystonia include tardive dystonia, posthypoxic dystonia, neuroacanthocytosis, pantothenate kinase-associated neurodegeneration, and Lesch-Nyhan syndrome.

Method: We summarize three children with pantothenate kinase-associated neurodegeneration and tongue protrusion dystonia. Read More

View Article and Full-Text PDF
February 2020

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

J Neurol Neurosurg Psychiatry 2019 12 10;90(12):1317-1323. Epub 2019 Jul 10.

Georgetown University, Washington, District of Columbia, USA.

Objective: To evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD).

Method: Patients with TD who completed the 12 week, phase 3, placebo-controlled trials were eligible to enter this open-label, single-arm study. The open-label study consisted of a 6 week dose-escalation phase and a long-term maintenance phase (clinic visits at Weeks 4, 6 and 15, and every 13 weeks until Week 106). Read More

View Article and Full-Text PDF
December 2019

Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.

J Clin Psychopharmacol 2019 Jul/Aug;39(4):336-343

Department of Psychiatry, Community Health Network, Indianapolis, IN.

Purpose/background: Dopamine receptor blocking agents (DRBAs), also known as antipsychotics, are medications widely used to treat a growing number of mental health diagnoses. However, their utility is limited by the potential to cause serious adverse movement reactions. Akathisia, dystonia, parkinsonism, and tardive dyskinesia (collectively known as extrapyramidal symptoms or EPSs) are associated with reduced social and occupational functioning, negative patient attitudes toward treatment, and nonadherence to pharmacotherapy. Read More

View Article and Full-Text PDF
February 2020

[Neurosurgical treatment of dystonia].

Ugeskr Laeger 2019 May;181(20)

In this review, we present evidence of treatment effect with deep brain stimulation (DBS) in patients with isolated forms of dystonia with generalised-, segmental- and focal phenotypes as well as tardive dystonia and dyskinetic cerebral palsy. Dystonia is a heterogeneous movement disorder, which can be disabling and difficult to treat. Patients with dystonia, who do not experience relief with medication and botulinum toxin, may be candidates for DBS. Read More

View Article and Full-Text PDF

Dystonia and Parkinson's disease: What is the relationship?

Neurobiol Dis 2019 12 9;132:104462. Epub 2019 May 9.

Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University of Toronto, Toronto, Canada. Electronic address:

Dystonia and Parkinson's disease are closely linked disorders sharing many pathophysiological overlaps. Dystonia can be seen in 30% or more of the patients suffering with PD and sometimes can precede the overt parkinsonism. The response of early dystonia to the introduction of dopamine replacement therapy (levodopa, dopamine agonists) is variable; dystonia commonly occurs in PD patients following levodopa initiation. Read More

View Article and Full-Text PDF
December 2019

Drug-induced movement disorders.

Aust Prescr 2019 Apr 1;42(2):56-61. Epub 2019 Apr 1.

Movement Disorders Unit, Department of Neurology, Westmead Hospital, Sydney.

Many Therapeutic And Illicit Drugs Can Cause Movement Disorders Antipsychotics And Antiemetics Are Most Commonly Implicated:

The Time Of Onset Of The Movement Disorder May Be Acute Subacute Or Chronic The Severity Can Range From Mild To Severe And Life-threatening:

Early Recognition Of A Drug-induced Movement Disorder Is Essential To Allow For Prompt Intervention This Includes Stopping The Offending Drug Supportive Care And Sometimes Other Pharmacological Treatment: Read More

View Article and Full-Text PDF

Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol.

Exp Neurol 2019 08 26;318:61-70. Epub 2019 Apr 26.

Department of Psychology, University of Memphis, Memphis, TN 38152, USA. Electronic address:

GNAL encodes guanine nucleotide-binding protein subunit Gα(olf) which plays a key role in striatal medium spiny neuron (MSN)-dopamine signaling. GNAL loss-of-function mutations are causally-associated with isolated dystonia, a movement disorder characterized by involuntary muscle contractions leading to abnormal postures. Dopamine D2 receptor (D2R) blockers such as haloperidol are mainstays in the treatment of psychosis but may contribute to the development of secondary acute and tardive dystonia. Read More

View Article and Full-Text PDF

Response to Letter to the Editor.

Tremor Other Hyperkinet Mov (N Y) 2019 6;9:630. Epub 2019 Feb 6.

Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, US.

In Response To: Walker RH. Reply to: Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov. Read More

View Article and Full-Text PDF